The National Cancer Institute is sponsoring a collaborative clinical trial called the Lung Cancer Master Protocol, or Lung-MAP, for patients with squamous cell carcinoma. Foundation Medicine's genetic-sequencing technology will be used to screen patients for genetic alterations that might be related to their cancer, and patients will be randomly grouped into one of five treatment arms. Participants include the Foundation for the NIH, SWOG Cancer Research, Friends of Cancer Research, Amgen, Genentech, Pfizer, AstraZeneca and its MedImmune unit, the Bonnie J. Addario Lung Cancer Foundation, the American Cancer Society, Free to Breathe, the Lung Cancer Alliance, LUNGevity and Uniting Against Lung Cancer.

Related Summaries